Apollo Quickview (CASRN 74115-24-5)

Status of Data for Apollo

File First On-Line: 01/31/1987; Last Significant Revision: 06/01/1991

Category (section)	Status	Last Revised
Oral RfD Assessment	On-line	11/01/1989
Inhalation RfC Assessment	No data
Carcinogenicity Assessment	On-line	10/01/1993

Synonyms

74115-24-5 88025-82-5 Apollo Apollo 50W 3,6-bis(2-Chlorophenyl)-1,2,4,5-tetrazine

Bisclofentezin Bisclofentezine Clofentezine NC 21314 1,2,4,5-Tetrazine, 3,6-bis(2-chlorophenyl)-

Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect	Point of Departure*	UF	MF	RfD
Liver effects; organ weight changes	NOEL : 1.25 mg/kg-day	100	1	1.3 x10-2 mg/kg-day

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

• Principal and Supporting Studies (Oral RfD)
  • 1-year feeding dog study, BFC Chemicals, Inc., 1984
• Confidence in the Oral RfD
  • Study -- High
  • Database -- High
  • RfD -- High

Top of page

---

Reference Concentration for Chronic Inhalation Exposure (RfC)

Not Assessed under the IRIS Program.

Top of page

Carcinogenicity Assessment for Lifetime Exposure

• Weight-of-Evidence Characterization
  • C (Possible human carcinogen)
• Weight-of-Evidence Narrative:
  • Based on an increase in thyroid gland follicular cell tumors in male rats and supportive findings in pituitary/thyroid hormone activity.
  • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

---

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

• Not Assessed under the IRIS Program.

---

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

• Not Assessed under the IRIS Program.